TerminatedPhase 1NCT02846376
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hackensack Meridian Health
- Principal Investigator
- Andrew Pecora, MDHackensack UMC
- Intervention
- Nivolumab(drug)
- Enrollment
- 8 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2019 – 2023
Study locations (1)
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02846376 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04460950Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGNCT03058588Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic SyndromesAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia